Physician

Huayang Tang, M.D.

According to 2025 Medicare claims, Huayang Tang, M.D. (NPI: 1750341327) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hernando, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34608-1329.

Tang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,200 traditional Medicare patients, billed 588,860 HCPCS/CPT codes, and received $6,111,162 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 5,343 prescription claims across 619 beneficiaries totaling $5,996,004 in drug costs, led by Revlimid (Lenalidomide). DME data shows 57 claims. Open Payments data shows 198 records totaling $3,789. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $2,064,431 to $5,996,004. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $15,774 to $3,625.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,603	582,190	$5,188,089
2016	1,458	587,224	$5,356,447
2017	1,354	997,581	$6,880,630
2018	1,362	812,536	$6,049,604
2019	1,278	644,427	$6,138,538
2020	1,033	480,777	$4,934,443
2021	1,061	460,404	$4,612,084
2022	1,033	521,269	$5,825,900
2023	1,189	573,184	$6,376,590
2024	1,200	588,860	$6,111,162

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	381	2,779	$2,064,431
2016	408	3,230	$3,060,492
2017	392	3,317	$2,946,299
2018	442	3,472	$3,181,752
2019	442	3,648	$3,225,825
2020	405	3,238	$2,899,843
2021	446	3,713	$3,212,408
2022	469	4,431	$4,554,276
2023	518	4,373	$5,310,761
2024	619	5,343	$5,996,004

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	22	239	$40,222
2016	N/R	169	$42,172
2017	N/R	75	$16,510
2018	N/R	101	$7,343
2019	N/R	38	$1,624
2020	N/R	31	$1,525
2021	N/R	44	$1,705
2022	N/R	103	$4,028
2023	11	97	$3,949
2024	N/R	57	$4,676

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	497	2,236	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	460	825	$65
96372	Injection of drug or substance under skin or into muscle	436	2,711	$10
36415	Insertion of needle into vein for collection of blood sample	985	3,855	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	968	4,106	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	70	1,855	$1,377,061
Kisqali	Ribociclib Succinate	46	1,288	$576,904
Pomalyst	Pomalidomide	17	476	$386,245
Welireg	Belzutifan	11	330	$306,667
Calquence	Acalabrutinib Maleate	20	600	$305,834

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	32	$2,433
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	N/R	12	$1,907
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	13	$336

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	198	$3,789	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Huayang Tang, M.D.?

Tedicare shows public-source Medicare data for Huayang Tang, M.D. (NPI 1750341327), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Huayang Tang, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Huayang Tang, M.D.?

Huayang Tang, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Huayang Tang, M.D. have Open Payments data?

Huayang Tang, M.D. has 198 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.